Sorafenib treatment in post-allogeneic stem cell transplant FLT3-mutated acute myeloid leukaemia (AML) patients resulted in significantly improved 2-year OS (sorafenib treated 38% n = 30 vs. allogenic transplant alone 9% n = 30; p = 0.0001 NCT02997202) [90] suggesting a possible application for T-ALL patients with high FLT3 expression who have received SCT. The gene discussed is FLT3; the disease is acute lymphoblastic leukemia.